Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
NCT07371611Phase 3Recruiting
- Sponsor
- Qunxing Li
- Start
- Jan 2026
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab in oral squamous cell carcinoma (OSCC) (2 arms), sponsored by Qunxing Li. Primary endpoint: Event-Free Survival at 2 years. Started Jan 2026; status: recruiting.
02
Drugs
sintilimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT07371611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371611.